While pricing erosion remains a challenge for generic APIs, new opportunities for generic molecules will unfold in FY26. A lot of drug developments held up during COVID-19 are now getting fast-tracked ...
Laurus Labs (CMP: Rs 603; Market cap: Rs 32,492 crore; Rating: Overweight) posted strong results in Q3FY25, led by a ramp-up in the CDMO (Contract Development and Manufacturing Organisation) business.
The bank expects to grow 2025 total revenue by 3%-5% with positive operating leverage of over 200 basis points, mostly in line with our expectations. We view expense discipline as a key part of ...